Slide 1: Exchange filing cover letter for investor presentation
Date: 6th May, 2025 To, To, The Manager, The Manager, Department of Corporate Services, Listing Department, BSE Limited National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, ‘Exchange Plaza’, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 533573 NSE
Slide 2: Alembic Pharmaceuticals Limited Investor Presentation Q4 FY25
May 06, 2025 Alembic Pharmaceuticals Limited Investor Presentation Q4 FY25 01
Slide 3: Safe Harbour Statement
Safe Harbour Statement The materials and information presented herein may include forward-looking statements, which reflect current expectations, projections, and assumptions. These statements are inherently subject to risks and uncertainties that could cause actual results or outcomes to differ mat
Slide 4: Quarterly Snapshot
Quarterly Snapshot Revenue INR +17% YoY R&D Key Highlights 17.70 9% of +5% QoQ Sales India Branded Business Bn Achieved an 8% year-over-year growth, with quarterly revenues reaching INR 5.45 billion. EBIDTA EBIDTA US Generics INR +9% YoY Margin Reported a 20% YoY increase, driven by the ramp-up of k
Slide 5: Revenue Snapshot
Revenue Snapshot Business Q4 FY25 Q4 FY24 Y-o-Y Q3 FY25 Q-o-Q 12M FY25 12M FY24 Y-o-Y Formulations India 5.45 5.03 8% 6.14 -11% 23.39 22.00 6.3% US 5.08 4.23 20% 5.21 -2% 19.57 17.30 13.1% Ex-US 3.75 2.62 43% 2.99 25% 12.43 10.52 18.2% API 3.42 3.30 4% 2.59 32% 11.33 12.46 -9.1% Total Revenue 17.70
Slide 6: India Business – FY25 Performance
India Business – FY25 Performance Revenue Q4 FY25 Growth: 8% INR Bn Revenue FY25 CAGR: 12% INR Bn 5.03 5.45 22.00 23.39 Specialty 0.98 19.26 20.63 Acute 0.82 Animal Health 14.96 1.48 1.61 2.73 2.86 Q4FY24 Q4FY25 FY21 FY22 FY23 FY24 FY25 Sales Mix Q4 FY25 Anti Diabetic • The India Branded Business re
Slide 7: Branded Business – Rx driven rankings
Branded Business – Rx driven rankings Top Brands with Rank and Market Share Driving overall Prescription Business *Figures in Mn Rank MS% Rank MS% BRANDS MAT MAT BRANDS MAT MAT FY 25* FY 25 FY 25* FY 25 129.1 0.24 45 AZITHRAL 1 31.6 BROZEET-LS 3 6.9 ALTHROCIN 1 87.5 ISOFIT 3 5.2 CRINA-NCR 1 28.5 ULG
Slide 8: Prescription & Therapy Focus
Prescription & Therapy Focus Gynaecology, Anti Diabetic, Ophthalmology and Dermatology have shown good growth. FY25 Growth Comparison Therapy APL Market* Gynaecology 10% 7% Anti Diabetic 15% 13% Ophthalmology 15% 7% Dermatology 11% 13% * Above market growth is based on respective molecule group. Sou
Slide 9: New Launches
New Launches New launches continue to perform well, with a strong pipeline poised to strengthen presence across key segments. FY25 Therapy Molecule Brands Launch INR Mn Dydrogesterone / ISOFIT/ISOFIT SR 2022 766 Dydrogesterone SR Gynecology Iron Ferric RICHAR-FCM/TUFEHART 2023 165 Gastrointestinal R
Slide 10: Animal Health Business
Animal Health Business Revenue Q4 FY25 Growth: 19% INR Mn Revenue FY25 CAGR: 24% INR Mn Q4FY25 4305 Q4FY24 3553 2806 2320 980 1841 820 Q4FY24 Q4FY25 FY21 FY22 FY23 FY24 FY25 Sales Mix Q4 FY25 • Alembic operates in the Livestock, Poultry, and Companion Animal segments. 34% Tonic • Market leader in Ha
Slide 11: Technology transforming business
Technology transforming business Introduced iPad-based engagement for field force to enhance brand communication with healthcare 1 professionals Migrated to Salesforce CRM for seamless field operations, ensuring a 360-degree view of HMPs in 2 real-time 3 Modernized data infrastructure via Snowflake
Slide 12: US Business
US Business Revenue Q4 FY25 Growth: 20% INR Bn Revenue – Last 5 Years INR Bn Q4FY25 21.63 19.57 Q4FY24 17.30 16.66 15.72 5.08 4.23 Q4FY24 Q4FY25 FY21 FY22 FY23 FY24 FY25 Approved ANDAs • Well-established US front end with strong customer base. Derma • 4 products launched in Q4 FY25; total of 163 pro
Slide 13: Ex-US Business
Ex-US Business Revenue Q4-FY25 Growth: 43% INR Bn Revenue – Last 5 Years CAGR: 12% INR Bn 4.00 12.43 3.00 10.52 2.00 3.75 2.62 1.00 8.52 7.79 7.75 0.00 Q4FY24 Q4FY25 • Achieved 43% YoY growth in Q4, driven by higher offtake and an optimized product mix • Key partnerships active in Europe, Canada, Au
Slide 14: API Business
API Business Revenue Q4-FY25 Growth: 4% INR Bn Revenue – Last 5 Years CAGR: 4% INR Bn 3.30 3.42 12.46 11.66 11.33 9.55 9.39 Q4FY24 Q4FY25 • Reported 4% YoY growth, led by increased volume offset by pricing pressures • Filed 5 US DMFs in Q4 FY25; cumulative filings with US FDA now stands at 140 • Con
Slide 15: R&D
R&D Dosage form wise ANDA approval and launch Significant investment in building capabilities Q4 FY25 FY25 15.8% INR Bn Dosage Forms 14.0% Approval* Launch Approval* Launch 12.8% OSD 1 2 14 8 7.8% R&D Spend 7.6% OSD - Onco 0 0 4 1 8.4 7.2 R&D % of Injectable - Gen 1 0 4 1 6.7 5.2 sales 4.8 Injectabl
Slide 16: Yearly Financials
Yearly Financials INR Bn Revenue EBIDTA Net Profit 66.72 10.53 10.53 62.29 9.61 # 56.53 6.65 53.06 6.16 5.84 7.79 # 4.97 # FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 EBIDTA margin % Capex ROCE % 25% * 5.75 20% 4.67 15% # 16% 4.12 16%*# 14% # 3.45 14%*# 15%*# FY22 FY23 FY24 FY25 FY22
Slide 17: Sustainability
Sustainability Targets: Enhancing ESG compliance * Organization’s GHG Emissions are verified and validated by SBTi. * Net-Zero through 1.5 Degree C Pathway * Commissioned 2nd 12 MW Solar Park at Bhatpur, Vadodara. Total Solar power capacity 24 by 2050 MW. * 21 % Reduction in Specific Water Consump
Slide 18: Strategic Roadmap
Strategic Roadmap Strategic Roadmap Business Initiatives in FY25 Plan for FY26 • Drive Customer execution behavior across the sales force to engage with customer even better thereby increasing market share. • Upgraded data platform by deploying SNOWFLAKE for • Usage of AI for better customer and emp
Slide 19: Strategic Roadmap
Strategic Roadmap Business Initiatives in FY25 Plan for FY26 • 40+ New Launches across EU, Canada, Australia & South Africa to further strengthen our footprint • 50+ Marketing Authorization applications planned to deepen portfolio strength • ~42 New filings in FY25 across our RoW markets and • Compl
Slide 20: Company Overview
Company Overview Alembic, 18
Slide 21: Company at a Glance
Company at a Glance Mission Prescribers in India Improve healthcare with innovation, commitment and trust 2,40,000 Team size Field Force 16,500 + 5,500 Manufacturing facilities Brands 9 204 ANDA filings Net Zero 266 (Mar 31, 2025 ) 2050 R&D Centres Products in US 2 163 19
Slide 22: Value Proposition
Value Proposition Developing specialty drug Supplying APIs to 60+ pipeline for India countries globally Established presence in Chile Exploring opportunities in & UAE Injectables Ranks 20th in the Indian Expanding product portfolio in formulations market US Consistent, High Dividend Strengthening pr
Slide 23: The Journey
The Journey 2012 Formed a JV, 2006 Rhizen, for NCE FDA approved API Research facility 2007 Acquired Dabur’s Indian Cardiology, GI and Gynecology 2013 brands 2019 Launched first Azithral crossed 1907 2010 2016 NDA with a Rs. 250 crore 2023 Established by Pharmaceutical Formed a JV, partner. mark as p
Slide 24: Robust Infrastructure
Robust Infrastructure Last USFDA Location Dosage Form Audit International Generics F1 – Panelav General Oral Solids July’24* Oncology Oral Solids Mar’24* F2 – Panelav Oncology Injectables Oct’24 F2 - Panelav F3 - Karkhadi General Injectables F3 – Karkhadi Mar’23* Ophthalmic F4 – Jarod General Oral S
Slide 25: Thank You
May 06, 2025 Thank You For further queries, please contact: Investor Relations Advisors : Mr. Ajay Desai Adfactors PR Pvt. Ltd. ajay.desai@alembic.co.in 022-6695 3681 Snighter Albuquerque snighter.a@adfactorspr.com Darshan Mankad darshan.mankad@adfactorspr.com 23